David Hay — Friday POW!: Gilead Sciences (GILD) — an explicit Buy at ~$133 (16% off the $157.29 high) where a $10.5B Q2 GAAP net loss is "an accounting event, not a business event": acquisition write-downs mask raised FY product-sales guidance of $30.1B, a 46.9% adjusted operating margin (~$14B adjusted operating income), >$12.5B of estimated FCF next year on a $163B cap (a 7.6% FCF yield) and net debt of only ~$13.4B; a ~70%-share HIV franchise with Biktarvy protected to 2036 funds the Trodelvy first-line oncology build-out, at 12-13x adjusted earnings vs the S&P's 20x with a 2.5% dividend, resting on the 200-day after the 2024 two-year breakout

The pick is Gilead Sciences (GILD) at ~$133, and the verdict is unambiguous: "We recommend a Buy for Gilead Sciences (GILD)." The whole thesis turns on one discrimination — the $10.5 billion GAAP net loss reported on August 4 is "an accounting event, not a business event," driven "almost entirely" by acquisition write-downs and upfront payments that GAAP requires to be expensed immediately, "rather than any deterioration in the company's operations." Underneath it, the same quarter raised full-year product-sales guidance to $30.1 billion, and Q1's 46.9% adjusted operating margin — "one of the highest in large-cap biopharma" — implies roughly $14 billion of annual adjusted operating income. Free cash flow is estimated "north of $12.5 billion next year," which on the $163 billion cap is "a most alluring 7.6% FCF yield," against net debt of only ~$13.4 billion ($8.6B cash vs a bit over $22B debt) — "it could repay nearly all of its debt should it choose to." The engine is HIV: ~70% U.S. share anchored by Biktarvy, "the world's most prescribed HIV regimen," patent-protected through 2036 — "in pharmaceutical terms, that is a license to print the cash" — with PrEP sales over $1B in Q2 and the once-weekly oral pill with Merck (ISLEND-1/2) positive at AIDS 2026. The transformation is oncology: Trodelvy now has first-line approvals in metastatic triple-negative breast cancer (US + EU) and, with Keytruda, in first-line metastatic lung — "these are not incremental label expansions." At 12-13× adjusted earnings vs the S&P's 20×, with a 2.5% dividend and the stock "resting on its 200-day moving average" after the spring-2024 two-year breakout — "the pause that refreshes." The bear case (IRA pricing on Biktarvy, acquisition-integration risk) is conceded and then bounded: "the bears need to be right about both… simultaneously."

One-line take: a single-name POW! — GILD an explicit Buy — built on the cleanest example this archive has of Haymaker's favourite setup: a quality franchise mispriced by an accounting artifact rather than by business deterioration. The framing is stated up front and is the reason to read the piece: "one of the more quietly compelling setups in large-cap biopharma… and the reason it is under the radar for most investors is the same reason we find it attractive." The artifact. Q2 2026 (August 4) produced a "$10.5 billion GAAP net loss… which is obviously not what you want to see," and Haymaker is explicit about the mechanical damage it does: "that number will appear in every screener, valuation tool, and news headline about Gilead for the next several months… it will make the stock look broken to investors who look at GAAP earnings without reading the footnotes." But it is "almost entirely a function of acquisition-related charges, such as upfront payments and write-downs… required to be expensed immediately under GAAP," and "these charges reflect long-duration assets whose value accrues over years." The reality underneath it is measured with three numbers taken from the same release: guidance was raised to $30.1B, the adjusted operating margin is 46.9% (Q1) — "a 46.9% adjusted operating margin on $30 billion in annual revenue produces approximately $14 billion in annual adjusted operating income" — and FCF is estimated "north of $12.5 billion next year," a 7.6% yield on the $163B cap. The balance-sheet check is the tell that the cash is real: $8.6B cash against "a bit over $22 billion in debt," so net debt ~$13.4B could be retired in roughly a single year of free cash flow. The engine. HIV is "the dominant commercial franchise… approximately 70% U.S. market share anchored by Biktarvy, the world's most prescribed HIV regimen," carrying "patent protection through 2036" — "in pharmaceutical terms, that is a license to print the cash that funds R&D, acquisitions, dividends, and buybacks for the better part of the next decade" — extended further by the lenacapavir estate. Two prevention milestones land in the quarter: PrEP sales exceeded $1B (the Yes2Go program), and the FDA accepted the Yeztugo filing for a once-weekly oral PrEP. The ISLEND-1/ISLEND-2 Phase 3s for a once-weekly oral HIV pill, "developed jointly with Merck," read out positively at AIDS 2026 in Rio. The transformation. Trodelvy — the antibody-drug conjugate from the criticised $21B Immunomedics purchase in 2020 — now holds US and EU first-line approvals in metastatic triple-negative breast cancer and a US first-line lung approval in combination with Keytruda. Haymaker insists on the distinction: "these are not incremental label expansions"; first-line indications "are among the largest oncology markets by patient volume and revenue potential," and the $21B price "is looking more defensible with each new approval." That also answers the bears directly: "uptake in first-line indications historically bears little resemblance to the niche second-line volumes the bears are modeling." Valuation. 12-13× adjusted earnings vs peers and the S&P at 20×; targets $120-$165, average ~$150 (≈14% upside at consensus, 25% at the high), with the dispersion itself informative — Leerink Market Perform at $127 against Morgan Stanley at $165 "reflects genuine debate about whether the oncology transformation justifies the acquisition spend." The technical. GILD "achieved a two-year breakout in the spring of 2024" and has trended up since, but "on a forward P/E basis it's just as cheap now as it was when it broke out"; after a nine-month pullback it "is resting on its 200-day moving average (yellow line)… this is the pause that refreshes and it's poised to run again" — the same retest-not-chase entry discipline used on crude on Aug-4. Arguing the other side is unusually honest: IRA pricing on Biktarvy before 2036 is "the most credible bear case… we'd be lying if we said it's completely bogus," and acquisition-integration risk across Arcellx, Tubulis and Oral Medicines means "if any acquired pipeline asset fails in development, the write-downs compound." The rebuttal is a burden-of-proof test rather than a denial: "the bears need to be right about both IRA pricing and acquisition integration simultaneously to justify the current discount… a higher burden of proof than the current price implies." Target outcome: "a re-rating to approximately 15-16× adjusted earnings as the GAAP loss normalization removes the… selling overhang and the oncology revenue ramp becomes visible in consecutive quarterly results." (No Buys / Trims-Holds / Sells portfolio tables accompanied this issue.)

1. Stocks & names mentioned

Ticker	Name	Research	View	What he said	At
GILD	Gilead Sciences	QT · SA · STK · FA	Positive	The week's pick — "We recommend a Buy for Gilead Sciences (GILD)." At ~$133, 16% below the $157.29 52-week high (range $107.75–$157.29), "one of the more quietly compelling setups in large-cap biopharma… the reason it is under the radar is the same reason we find it attractive." The mispricing is an accounting artifact: the $10.5B Q2 GAAP net loss (Aug 4) is "almost entirely… acquisition-related charges… required to be expensed immediately under GAAP," so it is "an accounting event, not a business event" — but "that number will appear in every screener, valuation tool, and news headline… for the next several months." The operating reality from the same release: FY product-sales guidance raised to $30.1B, a 46.9% adjusted operating margin (Q1) implying ~$14B of annual adjusted operating income, and FCF estimated "north of $12.5B next year" — "a most alluring 7.6% FCF yield" on the $163B cap — against net debt of only ~$13.4B ($8.6B cash vs >$22B debt), i.e. "it could repay nearly all of its debt" in about a year of FCF. The engine is HIV: ~70% U.S. share on Biktarvy, "the world's most prescribed HIV regimen," protected through 2036 — "a license to print the cash that funds R&D, acquisitions, dividends, and buybacks for the better part of the next decade" — plus PrEP sales over $1B in Q2 (Yes2Go), the accepted Yeztugo weekly-oral-PrEP filing, and the positive ISLEND-1/2 readout at AIDS 2026 for a once-weekly oral pill developed with Merck. The transformation is Trodelvy (from the $21B Immunomedics deal): first-line approvals in metastatic triple-negative breast cancer (US + EU) and, with Keytruda, first-line metastatic lung — "these are not incremental label expansions," and "uptake in first-line indications historically bears little resemblance to the niche second-line volumes the bears are modeling." Valuation: 12-13× adjusted earnings vs peers and the S&P's 20×, a 2.5% dividend ($0.79/qtr), targets $120-$165 (avg ~$150) with Leerink at $127 vs Morgan Stanley at $165. Technically, after the spring-2024 two-year breakout it is "just as cheap now on a forward P/E basis as it was when it broke out" and is "resting on its 200-day moving average… the pause that refreshes." Risks conceded — IRA pricing on Biktarvy ("we'd be lying if we said it's completely bogus") and integration risk across Arcellx/Tubulis/Oral Medicines — but "the bears need to be right about both… simultaneously." Expected outcome: a re-rating to ~15-16× adjusted earnings.	read ↗
MRK	Merck & Co.	QT · SA · STK · FA	Neutral	Named twice, both times as Gilead's counterparty rather than as a call. As co-developer: "the ISLEND-1 and ISLEND-2 Phase 3 trials for its new, once-weekly oral HIV pill (developed jointly with Merck) read out positively at the AIDS 2026 conference in Rio. The data confirmed that the drug suppressed the virus, supporting regulatory filings for what would be the first-of-its-kind HIV therapy." And via its franchise drug: the FDA "approved Trodelvy in combination with Keytruda for first-line metastatic non-small cell lung cancer" — one of the two label expansions Haymaker calls "not incremental." No view is taken on Merck's shares; it is context for GILD's pipeline and oncology reach.	read ↗

"View" is Haymaker's stance in this post. GILD is the only rated recommendation (an explicit Buy); MRK is the HIV co-development partner and the owner of Keytruda, named as context rather than as a call. Referenced only (not rowed): Immunomedics (acquired 2020 for $21B — the source of Trodelvy, no longer separately listed) and the recent acquisitions Arcellx, Tubulis and Oral Medicines (the source of the Q2 write-downs); the products Biktarvy, lenacapavir, Yeztugo, Trodelvy, Yescarta, Tecartus, Keytruda and GS-2426; the sell-side houses Leerink (Market Perform, $127) and Morgan Stanley ($165); the Inflation Reduction Act Medicare price-negotiation regime; and the AIDS 2026 conference. No Buys / Trims-Holds / Sells portfolio tables accompanied this issue. Research: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis.

2. Talking points

The setup — under the radar for the reason it's attractive

"Gilead Sciences is one of the more quietly compelling setups in large-cap biopharma right now, and the reason it is under the radar for most investors is the same reason we find it attractive."
The price: "approximately $130 to $133, down 16% from its 52-week high of $157.29 and sitting in the middle of its 52-week range of $107.75 to $157.29."

The headline that creates the discount

"Yes, the Q2 2026 results released August 4 showed a $10.5 billion GAAP net loss, which is obviously not what you want to see."
"The number sounds catastrophic until you understand it is almost entirely driven by acquisition-related write-downs and upfront payments rather than any deterioration in the company's operations."

Why the artifact persists — screeners don't read footnotes

"That number will appear in every screener, valuation tool, and news headline about Gilead for the next several months. To many, it will make the stock look broken to investors who look at GAAP earnings without reading the footnotes."
The accounting rule doing the damage: upfront payments and write-downs on acquisitions are "required to be expensed immediately under GAAP" even though "these charges reflect long-duration assets whose value accrues over years."

The operating reality, from the same release

The quarter that produced the loss also "delivered strong revenue growth in HIV and oncology, raised full-year product sales guidance to $30.1 billion," and generated the cash needed for a 2.5% dividend and an active buyback.
Q1 2026 for scale: revenue $6.96B, +4.4% (1.5% beat); adj. EPS $2.03 (6.3% beat); adj. operating income $3.27B at a 46.9% margin (4.7% beat), with the GAAP operating margin up to 37.2% from 33.5%.
The arithmetic Haymaker wants remembered: "a 46.9% adjusted operating margin on $30 billion in annual revenue produces approximately $14 billion in annual adjusted operating income. The GAAP loss is the accounting artifact of building the oncology business."

The cash test — FCF yield and a one-year debt paydown

"Free cash flow (FCF) is estimated to come in around north of $12.5 billion next year… that would be a most alluring 7.6% FCF yield" on the $163 billion market cap.
The balance sheet corroborates it: "$8.6 billion in cash versus a bit over $22 billion in debt. Thus, net debt is roughly $13.4 billion… if GILD hits its free cash flow target next year, it could repay nearly all of its debt should it choose to do so."

The HIV franchise — the cash engine funding everything else

"The dominant commercial franchise in HIV treatment, with approximately 70% U.S. market share anchored by Biktarvy, the world's most prescribed HIV regimen."
"Biktarvy… carries patent protection through 2036. In pharmaceutical terms, that is a license to print the cash that funds R&D, acquisitions, dividends, and buybacks for the better part of the next decade" — with the lenacapavir patent estate extending beyond that.

Prevention crosses $1B — and goes oral

"PrEP sales exceeded $1B in Q2 2026, a new milestone driven by lenacapavir Yes2Go and growing prevention market awareness."
"The FDA accepted Yeztugo application for once-weekly oral PrEP — potentially first long-acting pill for HIV prevention."

The Merck-partnered once-weekly pill

"The ISLEND-1 and ISLEND-2 Phase 3 trials for its new, once-weekly oral HIV pill (developed jointly with Merck) read out positively at the AIDS 2026 conference in Rio."
"The data confirmed that the drug suppressed the virus, supporting regulatory filings for what would be the first-of-its-kind HIV therapy."

Trodelvy — the $21B purchase getting more defensible

The asset: "the antibody-drug conjugate Gilead acquired through its 2020 purchase of Immunomedics for $21 billion… the clearest expression of what Gilead's oncology strategy can produce."
The approvals: US FDA in first-line metastatic triple-negative breast cancer ("one of the most difficult-to-treat cancers and a historically large unmet need"), European Commission approval for the same indication, and US approval in combination with Keytruda for first-line metastatic non-small cell lung cancer.
Why it matters: "These are not incremental label expansions." First-line metastatic TNBC and lung "are among the largest oncology markets by patient volume and revenue potential," and the $21B price, "criticized at the time as expensive, is looking more defensible with each new approval."

Valuation — 12-13× against an S&P at 20×

"Gilead trades at roughly 12-13x adjusted earnings on the underlying operating business, representing a significant discount to large-cap biopharma peers and to the S&P 500 at 20x."
"The analyst target range of $120 to $165 with an average around $150 implies approximately 14% upside at consensus and 25% at the high." The dispersion — "Leerink with Market Perform at $127… and Morgan Stanley at $165" — "reflects genuine debate about whether the oncology transformation justifies the acquisition spend."
Haymaker's side, and the reason: "We are on the bull side: Trodelvy's first-line approvals… have answered whether the drug reaches the largest markets. Uptake in first-line indications historically bears little resemblance to the niche second-line volumes the bears are modeling."

The chart — a 2024 breakout, and a retest to buy

"GILD achieved a two-year breakout in the spring of 2024. Since then, as is typical when this happens, it's had a robust rally. Naturally, it would have been nice to highlight this one back then but on a forward P/E basis it's just as cheap now as it was when it broke out."
"It has pulled over the last nine months. At this point, it is resting on its 200-day moving average (yellow line). In our appraisal, this is the pause that refreshes and it's poised to run again" — the same buy-the-retest discipline applied to crude on Aug-4.

Arguing the other side, 1 — IRA pricing on Biktarvy

"The most credible bear case is Inflation Reduction Act (IRA) pricing scrutiny on HIV. If Biktarvy is subject to Medicare drug price negotiation before its 2036 patent expiry, the revenue trajectory of the HIV franchise changes materially and the cash generation that funds the oncology transformation shrinks."
The honesty: "This is the risk driving Leerink's downgrade and we'd be lying if we said it's completely bogus."

Arguing the other side, 2 — integration risk compounds the write-downs

"Arcellx, Tubulis, and Oral Medicines in rapid succession each carry their own clinical execution risk, and the $10.5 billion Q2 GAAP loss is the accounting fallout of those commitments."
"If any acquired pipeline asset fails in development, the write-downs compound."

The rebuttal — both bears must be right at once

"Despite these risks, we think the bears need to be right about both IRA pricing and acquisition integration simultaneously to justify the current discount."
"In our view, that is a higher burden of proof than the current price implies." The argument is about the joint probability, not about dismissing either risk.

The bottom line — and the re-rating being played for

"GILD represents the dominant HIV franchise in the world at 12-13x adjusted earnings with a 2.5% dividend yield and a first-line oncology portfolio that posted two major approvals in a single quarter… a business generating $14 billion in annual adjusted operating income that the market is pricing at a 16% discount to its 52-week high because a $10.5 billion GAAP accounting charge made the Q2 headline look terrible."
"The setup is a quality franchise at a solid discount, created by accounting complexity rather than business deterioration." The pipeline — "once-weekly oral HIV treatment, Yeztugo PrEP, GS-2426, additional Trodelvy indications, CAR-T expansion" — is "the most clinically productive Gilead has assembled in a decade."
The target: "We anticipate a re-rating to approximately 15-16x adjusted earnings as the GAAP loss normalization removes the mandate-driven selling overhang and the oncology revenue ramp becomes visible in consecutive quarterly results." Verdict: "We recommend a Buy for Gilead Sciences (GILD)."

3. In plain English

A jargon-free note on why each name is cited. (Companion to the table above; renders on each name's consolidated page.)

GILD — Gilead Sciences Positive

Gilead is the company that dominates HIV medicine. Its main drug, Biktarvy, is the most-prescribed HIV treatment in the world and holds roughly 70% of the American market; its patents run to 2036. That is about as close as a drug company gets to a guaranteed income stream, and Hay's word for it is blunt: a licence to print the cash that pays for research, acquisitions, the dividend and the buyback for most of the next decade.

The reason the stock is cheap right now comes down to one misleading number. On August 4 Gilead reported a $10.5 billion loss. That sounds like a catastrophe, and it will show up in every stock screener and headline for months. But it is not money the business lost operating — it is the accounting treatment of companies Gilead bought. Under US accounting rules, when you buy a drug developer and pay upfront for its pipeline, you must write that cost off immediately, even though the drugs you bought will earn money for years. So the loss is a one-off bookkeeping charge for buying assets, not a sign the business went backwards.

What the business actually did in the very same quarter: it raised its full-year sales forecast to $30.1 billion. Its profit margin before those charges is 46.9%, one of the best in the industry, which works out to roughly $14 billion of real operating profit a year. Next year it expects to throw off more than $12.5 billion of free cash — cash left over after running and investing in the business. Against a company worth $163 billion, that is a 7.6% cash yield, which is high for a business of this quality. And it owes very little on a net basis: $8.6 billion of cash against $22 billion of debt, so about $13.4 billion net — one year of free cash flow would clear almost all of it.

The growth story is cancer. Trodelvy, a drug Gilead bought in 2020 for $21 billion (a price everyone called too high at the time), has just been approved as a first treatment — not a last resort — for the hardest-to-treat form of breast cancer in both the US and Europe, and for lung cancer in combination with Merck's Keytruda. That distinction matters more than it sounds: first-line means every newly diagnosed patient is a candidate, so the number of people treated is far larger than the "after everything else failed" market the sceptics have modelled. On the HIV side, a once-weekly pill developed with Merck worked in its final-stage trials, and prevention drugs (PrEP) passed $1 billion in sales in a single quarter for the first time.

The price: about 12-13 times earnings, against an S&P 500 at 20 times, with a 2.5% dividend while you wait. Technically the stock broke out of a two-year range in spring 2024, ran, and has now drifted back to its 200-day moving average — the rough average price of the past year, which Hay treats as the place to buy rather than chase. His phrase: "the pause that refreshes."

He does not dodge the risks. The first is that Medicare gets the power to negotiate Biktarvy's price before 2036, which would shrink the cash engine paying for everything else — he admits this one is real. The second is that the companies Gilead just bought (Arcellx, Tubulis, Oral Medicines) fail in the clinic, forcing more write-offs. His answer isn't that either is impossible; it's that the current share price only makes sense if both go wrong at the same time, and that's a lot to assume. If they don't, he expects the stock to re-rate to 15-16 times earnings once the ugly headline number rolls off and the cancer revenues start showing up quarter after quarter. Verdict: buy.

Summary derived from the paid Haymaker newsletter (text in transcript.txt) for personal study. Not investment advice. © Haymaker / David Hay for source material.